المؤلفون: Choueiri, Toni K., Escudier, Bernard, Powles, Thomas, Tannir, Nizar M., Mainwaring, Paul N., Rini, Brian I., Hammers, Hans J., Donskov, Frede, Roth, Bruce J., Peltola, Katriina, Lee, Jae Lyun, Heng, Daniel Y. C., Schmidinger, Manuela, Agarwal, Neeraj, Sternberg, Cora N., McDermott, David F., Aftab, Dana T., Hessel, Colin, Old, Christian Scheff, Schwab, Gisela, Hutson, Thomas E., Pal, Sumanta, Motzer, Robert J., METEOR Investigators

المساهمون: Department of Oncology, Clinicum

المصدر: Translational Andrology and Urology
Choueiri, T K, Escudier, B, Powles, T, Tannir, N M, Mainwaring, P N, Rini, B I, Hammers, H J, Donskov, F, Roth, B J, Peltola, K, Lee, J L, Heng, D Y C, Schmidinger, M, Agarwal, N, Sternberg, C N, McDermott, D F, Aftab, D T, Hessel, C, Scheffold, C, Schwab, G, Hutson, T E, Pal, S, Motzer, R J & METEOR Investigators 2016, ' Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial ', The Lancet Oncology, vol. 17, no. 7, pp. 917-27 . https://doi.org/10.1016/S1470-2045Test(16)30107-3

مصطلحات موضوعية: Male, 0301 basic medicine, Pyridines, law.invention, chemistry.chemical_compound, TARGETED THERAPY, PROGNOSTIC-FACTORS, 0302 clinical medicine, Randomized controlled trial, law, Antineoplastic Combined Chemotherapy Protocols, Clinical endpoint, Anilides, Hazard ratio, Middle Aged, Prognosis, CANCER, Kidney Neoplasms, 3. Good health, Survival Rate, Editorial, Oncology, 030220 oncology & carcinogenesis, SURVIVAL, Female, medicine.drug, Sorafenib, medicine.medical_specialty, Cabozantinib, 3122 Cancers, Urology, 03 medical and health sciences, medicine, Humans, Everolimus, COMBINATION, Carcinoma, Renal Cell, Survival rate, Aged, Neoplasm Staging, III TRIAL, business.industry, EAU GUIDELINES, EFFICACY, Interim analysis, Surgery, SORAFENIB, 030104 developmental biology, chemistry, METASTASIS, business, Follow-Up Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4bc4d936baaba5695527e426e9f6234Test
https://doi.org/10.1016/s1470-2045Test(16)30107-3

المؤلفون: Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Mainwaring, Paul N, Rini, Brian I, Donskov, Frede, Hammers, Hans, Hutson, Thomas E, Lee, Jae-Lyun, Peltola, Katriina, Roth, Bruce J, Bjarnason, Georg A, Géczi, Lajos, Keam, Bhumsuk, Maroto, Pablo, Heng, Daniel Y C, Schmidinger, Manuela, Kantoff, Philip W, Borgman-Hagey, Anne, Hessel, Colin, Scheffold, Christian, Schwab, Gisela M, Tannir, Nizar M, Motzer, Robert J, Schöffski, Patrick

مصطلحات موضوعية: Adult, Aged, 80 and over, Anilides, Antineoplastic Agents, Carcinoma, Renal Cell, Disease-Free Survival, Everolimus, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Pyridines, Quality of Life, Sirolimus, Survival Analysis

وصف الملف: 545699 bytes; application/pdf

العلاقة: New England Journal of Medicine vol:373 issue:19 pages:1814-23; https://lirias.kuleuven.be/handle/123456789/540820Test; https://lirias.kuleuven.be/bitstream/123456789/540820/1//Cabozantinib+versus+Everolimus+in+Advanced+Renal-Cell+Carcinoma.pdfTest

الإتاحة: https://lirias.kuleuven.be/handle/123456789/540820Test
https://lirias.kuleuven.be/bitstream/123456789/540820/1//Cabozantinib+versus+Everolimus+in+Advanced+Renal-Cell+Carcinoma.pdfTest